Retrospective validation among 18 million patients

In a retrospective study among 18 million patients who were dispensed a prescription opioid during 2009 – 2013 in one of the largest US commercial health plan claims databases, as shown below in the “Predicted vs. Observed” comparison, Venebio Opioid Advisor demonstrated a remarkable level of predictive accuracy.

Venebio will begin beta site testing in early 2017 and is currently looking for development partners. Ideal partners include ACOs, large healthcare systems, large multi-location family medicine practices, large multi-location orthopedic practices, pain clinics and dental clinics.

Venebio has also received a $1.5 million research grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH).

predictedprobabilityvenebio

Request More Information

Interested in learning more or participating as a development partner or beta site?

Request More Information